Literature DB >> 9496417

Levofloxacin for drug-resistant Mycobacterium tuberculosis.

C A Peloquin, S E Berning, G A Huitt, M D Iseman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9496417     DOI： 10.1345/aph.17167

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN： 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  2 in total

1.  Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients.

Authors:  S C Piscitelli; K Spooner; B Baird; A T Chow; C L Fowler; R R Williams; J Natarajan; H Masur; R E Walker
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.

Authors:  Cynthia A Sanders; Rachel R Nieda; Edward P Desmond
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.